Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 07/23/04 → 04/29/11 |
Funding
- Merck and Company: $20,527.20
Safety, Immunogenicity, and Efficacy of Quadrivalent HPV (Types 6,11,16,18) L1 Virus-Like Particle(VLP) Vaccine in Mid-Adult Women-The FUTURE III(Females Uninted to Unilaterally Reduce Endo/Ecto Cervical Cancer) Study
- Baker, David (PI)
- Garry, David (CoPI)
Project: Research